NCT03913949 2025-04-16A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesAscentage Pharma Group Inc.Phase 1 Active not recruiting74 enrolled
NCT04494503 2025-04-16Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLAscentage Pharma Group Inc.Phase 1/2 Recruiting123 enrolled